Table of Contents Table of Contents
Previous Page  76 / 114 Next Page
Information
Show Menu
Previous Page 76 / 114 Next Page
Page Background

72

NCCN Guidelines for Patients

®

Breast Cancer - Early-Stage

(STAGES I AND II)

, Version 1.2016

6

Endocrine therapy

Regimens

Regimens

Chart 6.2 Premenopausal women

Initial treatment

Extended treatment

• Tamoxifen for 5 years ± ovarian

suppression or ablation

If still premenopausal:

• Consider taking tamoxifen for another 5 years, or

• Stop taking endocrine therapy

If postmenopausal:

• Take aromatase inhibitors for 5 years, or

• Consider taking tamoxifen for another 5 years

• Aromatase inhibitor for 5 years + ovarian suppression or ablation

Chart 6.3 Postmenopausal women

Initial, sequential, and extended treatment

• Aromatase inhibitor for 5 years

• Tamoxifen for 2–3 years followed by an aromatase inhibitor to complete 5 years of endocrine therapy

• Tamoxifen for 2–3 years followed by an aromatase inhibitor taken for up to 5 years

• Aromatase inhibitor for 2–3 years followed by tamoxifen to complete 5 years of endocrine therapy

• Tamoxifen for 4.5 to 6 years followed by an aromatase inhibitor for up to 5 years

• Tamoxifen for 4.5 to 6 years then consider to keep taking to complete 10 years of endocrine therapy

• Tamoxifen for 5 years if aromatase inhibitors aren’t an option

• Consider tamoxifen for 10 years if aromatase inhibitors aren’t an option